Furthermore, the NSCLC cohort used is predominately comprised of early-stage patients with surgically resectable disease, which both limited the assessment of any correlation between CD40 expression and tumor stage and prevented the evaluation of CD40 distribution and CD40 as a prognostic marker in advanced stage disease. The gene discussed is CD40; the disease is non-small cell lung carcinoma.